Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

about

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

Item

http://www.wikidata.org/entity/Q42359768

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

@en

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

@nl

type

Item

label

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

@en

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

@nl

prefLabel

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

@en

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

@nl

P1476

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

@en

P2093

Monica Venere

http://www.w3.org/2001/XMLSchema#string

P2860

Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

FACT, a factor that facilitates transcript elongation through nucleosomes

FACT is a sensor of DNA torsional stress in eukaryotic cells.

Characteristics of stem cells from human neuroblastoma cell lines and in tumors

Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.

A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.

Histone chaperone FACT regulates homologous recombination by chromatin remodeling through interaction with RNF20.

The H2B ubiquitin ligase RNF40 cooperates with SUPT16H to induce dynamic changes in chromatin structure during DNA double-strand break repair.

Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

P304

174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/ATM.2017.03.46

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28480210

http://www.w3.org/2001/XMLSchema#string

P921

cbl-0137 free base

P932

5401662

http://www.w3.org/2001/XMLSchema#string